195 related articles for article (PubMed ID: 37900165)
1. Reimbursement decision-making system in Poland systematically compared to other countries.
Mela A; Rdzanek E; Jaroszyński J; Furtak-Niczyporuk M; Jabłoński M; Niewada M
Front Pharmacol; 2023; 14():1153680. PubMed ID: 37900165
[No Abstract] [Full Text] [Related]
2. AOTMiT reimbursement recommendations compared to other HTA agencies.
Mela A; Lis D; Rdzanek E; Jaroszyński J; Furtak-Niczyporuk M; Drop B; Blicharski T; Niewada M
Eur J Health Econ; 2024 Jan; ():. PubMed ID: 38261131
[TBL] [Abstract][Full Text] [Related]
3. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
4. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
5. Methods for the comparative evaluation of pharmaceuticals.
Zentner A; Velasco-Garrido M; Busse R
GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
[TBL] [Abstract][Full Text] [Related]
6. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020.
Pham C; Le K; Draves M; Seoane-Vazquez E
JAMA Intern Med; 2023 Apr; 183(4):290-297. PubMed ID: 36780147
[TBL] [Abstract][Full Text] [Related]
7. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
Lipska I; McAuslane N; Leufkens H; Hövels A
Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
[TBL] [Abstract][Full Text] [Related]
8. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
[TBL] [Abstract][Full Text] [Related]
9. A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland.
Kolasa K; Schubert S; Manca A; Hermanowski T
Health Policy; 2011 Oct; 102(2-3):145-51. PubMed ID: 21641074
[TBL] [Abstract][Full Text] [Related]
10. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
Stafinski T; Glennie J; Young A; Menon D
Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
[TBL] [Abstract][Full Text] [Related]
11. Health technology assessment in Poland and Scotland: comparison of process and decisions.
Kolasa K; Wasiak R
Int J Technol Assess Health Care; 2012 Jan; 28(1):70-6. PubMed ID: 22617739
[TBL] [Abstract][Full Text] [Related]
12. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
Trouiller JB; Laramée P
Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
[TBL] [Abstract][Full Text] [Related]
13. Chance of reimbursement for ADD-ON therapies in Poland and in the world - review of the reimbursement recommendations.
Borowiack E; Marzec M; Nowotarska A; Jarosz J; Orkisz A; Prząda-Machno P
Przegl Epidemiol; 2018; 72(1):99-109. PubMed ID: 29667385
[TBL] [Abstract][Full Text] [Related]
14. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
Maynou L; Cairns J
Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.
Blonda A; Barcina Lacosta T; Toumi M; Simoens S
Front Pharmacol; 2021; 12():750742. PubMed ID: 35126102
[No Abstract] [Full Text] [Related]
16. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
[TBL] [Abstract][Full Text] [Related]
17. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
Kleijnen S; Lipska I; Leonardo Alves T; Meijboom K; Elsada A; Vervölgyi V; d'Andon A; Timoney A; Leufkens HG; De Boer A; Goettsch WG
Ann Oncol; 2016 Sep; 27(9):1768-75. PubMed ID: 27329251
[TBL] [Abstract][Full Text] [Related]
18. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
[No Abstract] [Full Text] [Related]
19. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
Neumann D; Jabłecka A
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
[TBL] [Abstract][Full Text] [Related]
20. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
